Abstract

PREVENTIVE EFFECT OF VILDAGLIPTIN AND FENOFIBRATE ON DIABETIC NEUROPATHY IN WISTAR RATS

Savita D. Patil*, Nilesh N. Chavan*, Kishor V. Pachpute, Amit D. Patil,Vineet S. Zope, Mayur A. Chaudhari, Prabodh V. Sapkale

ABSTRACT

Objectives: Fenofibrate (PPARα) a lipid lowering drug and also Fenofibrate intervention and event lowering in diabetes (FIELD) effect and vildagliptin a new antidiabetic drug in type 2 diabetic patients, the present study aims to evaluate the preventive effect of vildgliptin and fenofibrate on diabetic neuropathy. Materials and Methods: The rats were subjected to severe diabetic treatment with fenofibrate and vildagliptin and their combination the change in diabetic condition was assessed by various biochemical plasma parameters like glucose, cholesterol, triglycerides, low density lipoprotein (LDL), high density lipoprotein (HDL), very low density lipoprotein (VLDL), pharmacological parameters like hot plate test, tail flick test, randall selitto test, cold allodynia and histopathological studies. Results: The combination effect of vildagliptin with fenofibrate shows improvement in diabetes by reducing the plasma glucose level and also improve in lipid level by significantly reducing the TG, LDL, VLDL cholesterol and recovered by HDL cholesterol, and diabetic neuropathy are also prevented which is supported by significantly evaluation in pharmacological parameters and histopathological reports. Conclusion : The present study shows that vildgliptin decreased plasma glucose and fenofibrate decreased lipid profile and hence it shows that prevents the diabetic neuropathy in alloxan induced diabetic rats.

Keywords: Vildagliptin, Fenofibrate, Alloxan, Diabetic Neuropathy.